4D Molecular Therapeutics CEO David Kirn disposes of 58,333 common shares worth $810,105.1 - FDMT News | Rallies4D Molecular Therapeutics CEO David Kirn disposes of 58,333 common shares worth $810,105.1
F
FDMT• CEO sells shares in 4D Molecular Therapeutics
- David Kirn, president, CEO, sold 58,333 shares of 4D Molecular Therapeutics common stock on Sept. 14, 2026.
- Sale priced at USD 13.9 per share, based on a weighted average.
- Post-transaction beneficial ownership totaled 767,486 shares.
•
